SC's life sciences industry responds to the challenge of COVID-19 see more
I just completed a radio interview with SC Business Review, focused exclusively on the all-consuming and seismic topic of the Coronavirus – which is dramatically impacting all our lives. As I made clear to interviewer Mike Switzer, any relevance of me being interviewed as opposed to our scientists and clinicians is tied to the privilege that SCBIO has of serving as a voice and accurate storyteller for the 600+ life sciences companies and entities that proudly call the Palmetto State home.
And there are incredibly meaningful and encouraging stories to share in the midst of this very real public health crisis – regarding SC companies and institutions that will positively impact patients across the state and nation with innovative and creative approaches they are actively, and very rapidly, undertaking.
Just a few exemplary SC examples include:
- MUSC Health was the first in the nation to uniquely provide both direct, timely, and online access to Coronavirus screening via their virtual care platform coupled with a drive-through specimen collection site for patients with possible COVID-19 symptoms or exposure. This was done in partnership with the developers (newest SCBIO Member, Trademark Properties) of the dramatically redeveloped Citadel Mall Epic Center, which is now home to MUSC Health’s West Ashley Medical Pavilion – as they worked closely to secure immediate approvals for the location of the collection site in the mall parking lot. If you or someone you know needs to be screened, log on to www.musc.care and use COVID19 as the promo code. This is FREE for all South Carolinians.
- Nephron Pharmaceuticals, a major national supplier of respiratory therapy medications badly needed by patients suffering from COVID-19, is aggressively ramping up their ability to increase production of 90 million sterile doses per month of targeted drug therapies with an additional 32 million doses, as they work with the FDA to have 3 new aseptic filling lines approved and brought online quickly to meet skyrocketing demands they are experiencing.
- Vikor Scientific has specifically dedicated 2,000 sq. ft of their brand new 22,000 sq. ft. headquarters and CLIA-certified and CAP-accredited lab facilities at WestEdge for COVID-19 testing as soon as approval is received from the FDA. They are in fact preparing 100,000 test kits to be available for shipment to customers as soon as Wednesday of this week – and are working closely with the FDA for continued guidance on expediting the approval process.
On the national front, there are also some encouraging stories emerging, including the most rapid launch of a possible new vaccine on record.
Moderna has already begun its first coronavirus vaccine trial in Washington State (the nation’s worst hot spot at present) with volunteers at Kaiser Permanente Research Institute in Seattle. Over the next 2 months, volunteers ages 18-55 will get two doses of the trial vaccine (known as mRNA-1273). Dr. Fauci of the national Coronavirus Task Force has confirmed that this 65-day development is the fastest ever accomplished for a new vaccine of this magnitude. And while widespread utilization of a newly approved vaccine is still likely 12-18 months away, gratefully progress is on track to achieve that. Also noteworthy are other vaccines and targeted therapies concurrently in the pipeline, involving companies such as Pfizer, Regeneron and Sanofi.
Finally, on a very personal note, each of us and our extended families are being dramatically impacted by this global pandemic and are encouraged to do our parts in mitigating the spread of this fearsome and highly contagious virus. After an extended battle with metastatic lung cancer, my dad peacefully passed away this past weekend, and regrettably his funeral will have to be limited to a private family graveside service (with a future memorial service to be scheduled once the health crisis has subsided). In an interesting juxtaposition of life & death, my nephew’s wedding this weekend has been compressed to a small family rehearsal dinner combined with a quiet ceremony in conjunction with the dinner. I’m certain that there will be a multitude of other similar stories from most of you regarding how we grapple and deal with this unprecedented event with no clear endpoint at present.
While all of this will ultimately be in our “rear view mirrors” at some point in the future through the power and innovation of our industry, our researchers, and our heroic healthcare providers, life and business as we know it will have to be dramatically different in the weeks – and possibly months – ahead. Expect a more virtual experience with SCBIO for the near future, and look to hear from us more often via electronic means ranging from e-blasts to social media efforts to increased website postings to webinars. I am fully confident that all of our life & health sciences companies and leaders will respond valiantly, and that this will bring out the best in us – with creative and even transformative solutions and strategies that will enable us to maintain momentum in our vital missions. And we will learn a great deal and grow through this challenging process – as our strength is truly forged in fire…
We will update you on various developments around COVID-19 and beyond and encourage all of you to share your stories of hope and progress as we collectively battle this formidable foe. Please don’t hesitate to reach out to our SCBIO team for any reason, and we are more grateful than ever for all of you.
Sam Konduros, CEO
BMS steps up to help newly uninsured patients see more
PRINCETON, N.J. – April 7, 2020 – Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic.
The expanded program offers access to any branded Bristol Myers Squibb medicine for free, including some of its most widely prescribed products, as well as those prescribed via telehealth services. The program features:
- Immediate access for patients who have lost their employment and health insurance;
- A simple, single point of entry;
- Streamlined enrollment process; and
- Vouchers to assist with continuity of care for several self-administered BMS medicines, for eligible patients
All Bristol Myers Squibb patient support programs, as well as, additional eligibility requirements, can be reached by calling (800) 721-8909 or by visiting BMS.com.
“The COVID-19 pandemic has created unprecedented financial challenges for patients and families, adding considerable new stress to the millions of Americans who have lost their jobs and health insurance,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol Myers Squibb. “As more patients face difficult decisions in their daily lives, it is important to continue their treatments.”
Bristol Myers Squibb’s Response to COVID-19
Bristol Myers Squibb recognizes this is a challenging time for everyone. The company will continue to take all necessary actions to promote public health and carry out its mission of providing life-saving medicines to the patients who depend on us. Please visit BMS.com to learn more about our actions to date.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
Power of Collaboration: South Carolina’s Humimic Medical Arming Healthcare Workers for the COVID-19 WarHumimic Medical is stepping up for South Carolina see more
As a growing number of healthcare workers join the front lines to battle the global COVID-19 pandemic, or Coronavirus, here in America, there is critical need for basic personal protective equipment (PPE) to protect them – PPE which is now in short supply in many areas across America.
South Carolina entrepreneurs and industry leaders are stepping up in unprecedented ways to protect these first responders and to defeat the global pandemic.
Joel Edwards, CEO of Greenville’s Humimic Medical, decided his organization could do something about it – even though his company did not manufacture essential equipment like face masks, face shields, swabs, or gloves. Edwards estimated that if his team could re-purpose their own product designs and manufacturing capacity, they could deliver a quality version of these critical supplies at relatively low price-points – mirroring the approach for their existing synthetic gel and medical trainer products. With help from Deborah Herbert, President of Multiplastics in Mt. Pleasant, the company had plans and suppliers in place in less than 48 hours to deliver 80,000+ face shields over the next few weeks.
“As we sat around the table during a team meeting last week, we found ourselves asking each other how we can help,” said Edwards. “We knew we had to make something happen fast to make a difference, because healthcare workers don’t need something 3-4 weeks from now, they need it now.”
The Humimic team picked up drafting pencils and phones to devise a plan they could execute quickly, and had designs and suppliers lined up within one day and working prototypes ready to scale up 24 hours later.
The speed and agility demonstrated by Humimic Medical is not only a testament to the company’s ability to pivot and respond to market needs, but also showcases the rich, collaborative ecosystem that has emerged within South Carolina. Edwards was able to leverage relationships with physicians in a nearby health system to validate the design, tap vendor and supplier relationships through South Carolina’s Department of Commerce, and gain key insights and connections through groups like SCBIO, the South Carolina Biotechnology Industry Organization, which serves as the life science community’s catalyst for building, advancing and growing the industry.
Added SCBIO President and CEO Sam Konduros, whose team was able to rapidly connect Humimic with key contacts to deliver the new face shields where they are needed most, “We continue to live our mission of being the life sciences industry convener, and that’s more important than ever right now.”
“SCBIO has been a tremendous asset in this process” said Edwards. “Their team has walked right alongside of ours to ensure we maximize this opportunity to serve our front-line healthcare workers.”
He also hinted that Humimic Medical isn’t stopping with face shields either, as they work to develop other key supplies in short supply including a novel nasal swab and innovative re-usable face masks.
“The need is great, and we’re committed to making a difference during this time of need,” he added.
About Humimic Medical:
Humimic Medical is a rapidly growing medical trainer and synthetic gel manufacturing company based in Greenville, SC. The company is driven by innovative product design, world-class customer service, and fueled by robust collaborative partnerships with universities and healthcare providers. Humimic Medical utilizes its proprietary synthetic gel blend to more closely represent human tissue elasticity and maintain recyclable/reusable qualities that no other product line currently offers delivered at a significantly lower price point than any existing products.
Zylo nominated to BIO contest see more
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has been nominated as a finalist for the Buzz of BIO Contest, which recognizes the most innovative companies in the life sciences.
BIO is the world’s largest biotech association. Among other conferences, the association sponsors the 2020 BIO International Convention each year, with almost 20,000 attendees. It takes place in San Diego this year in June, where the winner of Buzz of BIO will be announced.
Each finalist was asked to submit the three compelling reasons to vote for them. Zylö’s reasons are summarized as follows:
1. Zylö’s endocannabinoid-loaded Z-pod™ solution is showing striking results in a lupus model... Lupus affects women and people of color disproportionately and has tragic quality-of-life ramifications.
2. Our nitric-oxide-releasing Z-pod™ topical solution is showing compelling results in an Erectile Dysfunction model (where ED is secondary to prostatectomy, a condition that is not treatable with Viagra et al.); this solution should translate well as a treatment for older women with sexual dysfunction.
3. Our technology is disruptive and affordable... and we plan on keeping it that way.
Scott Pancoast, Zylö CEO and founder, stated “This is a huge honor and reflects the incredible innovation taking place in our lab from Andrew Draganski PhD, scientific founder, and scientists Eric Renne (M.S., U.C.) and Clay Tucker (M.S., Clemson). We encourage folks in the Upstate to vote in an effort to continue this region’s winning ways in the world of technological innovation.”
About Zylö Therapeutics: Zylö has developed a breakthrough topical delivery system that extends the duration-of-effect, improves the solubility/targeting, and/or enhances the product performance of many therapeutic agents. Notably, the Z-pod™ technology platform has enabled the Patchless Patch™ concept and has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerful—and short-lived—biomolecules produced by our bodies. For more details please visit our web site, www.zylotherapeutics.com and follow us on Twitter (@ZyloTherapies).
Blinktbi of Charleston, SC pinpoints concussions see more
A startup that grew out of research at the Medical University of South Carolina and The Citadel has hit the market and closed on a new round of funding.
Blinktbi Inc.’s EyeStat device, now being sold to schools and athletic programs, puffs food-grade carbon dioxide into a subject’s eye, triggering the blink reflex. Then, high-speed cameras within the device capture thousands of images and gauge how long it took for the person to blink.
The upstart raised nearly $5 million in 2017, its first year. Those early funds were used in part to finance ongoing research at The Citadel to prove the device can be used to detect concussions and other maladies.
Ryan Fiorini, Blinktbi’s chief operations officer, said the EyeStat prototype weighed 100 pounds, and it utilized a gaming computer to process the images.
The next job was to cut it down to size.
“It didn’t fit in the back of my full-size SUV,” said Fiorini, who has a doctorate immunology and microbiology from MUSC. “We rolled that into the engineer’s office and said, ‘We need this to be four-and-a-half pounds.’”
They were able to pull it off.
The company cleared a formidable hurdle at the end of 2019, when the U.S. Food and Drug Administration gave Blinktbi permission to market its device, after a rigorous review process that took months to complete. One study published in 2013 found the FDA’s process to get medical devices to market from the idea phase typically takes between three and seven years.
Now free to begin selling EyeStat, Fiorini said the company is leasing the technology to lessen the blow of the device’s full cost of about $10,000.
The latest round of funding, for about $6 million, will help offset the costs of manufacturing the medical devices, to make that option possible.
Fiorini said organizations can rent EyeStat for around $200 per month.
One day, the company hopes insurance will cover the use of the technology.
The University of Pittsburgh Schools of the Health Sciences estimated the number sports-related concussions every year falls between 1.7 million and 3 million. About 300,000 are football injuries. Half go unreported.
Concussions happen when a blow to the head causes the brain to bounce around in the skull, leading to a chemical response, according to the Centers for Disease Control and Prevention. Those chemical changes make the brain more sensitive to stress until it heals.
The CDC found in one study that children and teens account for 65 percent of all concussions.
Fiorini’s own son suffered a concussion when he fell off a dock as a toddler.
“What we would come to find out is that there was no way to test him,” Fiorini said in a TEDx talk in Charleston last year.
Studies of how the blink reflex can indicate diseases like Parkinson’s and schizophrenia date back to the 1950s. But no tool has been developed in the intervening decades to use the response to help with diagnosis.
Dr. Nancey Tsai, a neurosurgeon at MUSC, came up with the idea for a portable machine that could measure the blink reflex in 2011.
From there, the Zucker Institute for Applied Neurosciences, which is embedded within MUSC, helped to license the technology. Mark Semler, CEO of the institute and now an adviser to Blinktbi, said the startup is the second in the institute’s portfolio to pass FDA clearance.
“The market is huge, because there’s no good option out there,” Semler said. “The blink can’t be cheated.”
Right now, Fiorini said the company has fewer than 10 employees working out of its office on Rutledge Avenue. Among its advisers are heavy-hitters in the world of sports, including Danny Morrison, the former president of the Carolina Panthers, Steve Smith, a longtime wide receiver in the NFL, and Harvey Schiller, former executive director of the United States Olympic Committee and former president of the International Baseball Federation.
Looking forward, Blinktbi is researching whether its technology could help to detect Alzheimer’s disease and multiple sclerosis.
Fiorini said he can see EyeStat in the hands of police for field tests, giving officers an immediate, objective measure of sobriety — though each new application for the device would require a new round of FDA approvals.
Life sciences is booming across South Carolina, experts report see more
The economic future of South Carolina is being profoundly impacted by a rising industry sector that has unexpectedly achieved the distinction of becoming the fastest-growing component of the Palmetto State’s knowledge economy.
Not automotive, not aerospace, but life sciences—a huge and multifaceted trillion-dollar-plus global industry that averages almost triple the R&D of all others, comprised of multiple segments, including drugs and pharmaceuticals, medical devices and equipment, digital health solutions, research-testing-medical labs, bio-science distribution, bio-ag and other life sciences support organizations.
The pharmaceutical segment in the U.S. alone employs approximately 3.5 million people, which exceeds the population of many states. Meanwhile, the medtech and digital health segments also continue to ramp-up dramatically, fueled by innovation and disruptive global trends ranging from the transformation of healthcare delivery to the enormous impact of artificial intelligence.
According to SCBIO’s just released statewide S.C. Life Sciences Strategic Plan (Version 2.0 covering 2019-2021), an influx of new firms into the Palmetto State coupled with a comprehensive recount effort has surprisingly revealed that the number of life science companies with a presence in the Palmetto State has risen to more than 650—a figure which is over 200 more than were recognized in an initial economic impact study conducted approximately three years ago.
That foundational study funded by the state Department of Commerce and SCRA revealed an annual life sciences economic impact now conservatively approaching $12 billion, with more than 43,000 direct and indirect employees receiving wages almost double the state’s average, and an employment growth rate twice that of South Carolina as a whole. Perhaps even more compelling is the fact that life science entities are now present in 43 of 46 SC counties.
Established starring players in the Palmetto State’s rapidly evolving life sciences constellation such as Nephron Pharmaceuticals in West Columbia have grown from 400 employees to over 1,100 in the same time frame, with an accompanying capital investment close to $400 million dollars. Long-time South Carolina life science companies such as ZEUS Industrial Products in Orangeburg, Clemson University spin-out Poly-Med Inc., Sumter’s BD and Charleston’s Charles River Laboratories are achieving record employment numbers boosted by a growing global customer base.
Concurrently, new South Carolina biotech and medtech industry stars recently coming on line such as Thorne Research in Berkeley County and Arthrex in Anderson County have invested tens of millions of dollars in state-of-the-art facilities and are rapidly ramping up to projected employment levels in the hundreds.
Equally encouraging is the fact that scores of highly innovative early-stage life sciences companies like Charleston’s Firststring Research Inc.and Greenville’s Humimic Medical are becoming deeply rooted and committed to building their promising futures in South Carolina. This is a testament to the fact that a robust life sciences industry ecosystem is forming and maturing that not only supports larger scale advanced manufacturing operations, but can also foster and support innovative start-ups and early stage (pre-revenue) companies that must be uniquely bolstered in their early developmental years with a myriad of sophisticated resources, talent and funding sources in order to successfully enter the marketplace.
In years past, a multitude of promising, young South Carolina-born companies often left the state in order to obtain crucial funding and unique talent in more established bastions of life sciences such as Boston, the West Coast or even the nearby Research Triangle in North Carolina.
Gratefully, South Carolina is becoming a rising destination for both mature and early-stage life science companies that are fueled by all three of our major research universities and their extraordinary life sciences core competencies, renowned institutes such as the Greenwood Genetics Center, medical schools anchoring three major regions, the MUSC and Prisma Health science centers, and major healthcare providers.
They are also tapping into a growing bullpen of content experts in the Palmetto State ranging from experienced FDA navigators to reimbursement specialists to intellectual property attorneys and other highly specialized consultants
Based on the positive momentum of this burgeoning industry—which is virtually recession-proof and a huge diversification for South Carolina’s economy—hard-fought funding for SCBIO has reached a record high with new members joining forces with the organization on a weekly basis.
This crucial fuel is enabling unprecedented life sciences economic development strategies to be successfully mounted in the Palmetto State, including the active recruitment of a new generation of leading-edge life sciences companies into South Carolina from all over the world, in tandem and full alignment with vital state, regional and local partners—with recent economic development missions generating measurable results in Switzerland, Italy, Germany, Dubai (UAE), and across the U.S.
To achieve SCBIO’s bold vision of building the nation’s most industry-friendly and innovative life sciences ecosystem and business environment to fuel a knowledge economy in South Carolina, there is much work to be done—and it will be an endless journey. And in some respects, the Palmetto State is still somewhat fledgling as a global player in this complex and ever-changing industry. However, South Carolina’s progress over the past decade has been nothing short of remarkable, and the opportunities are endless and unlimited.
Life sciences is now uniquely igniting and demonstrably contributing to a brilliant future for the state of South Carolina. Please stay tuned—the best is yet to come.
Nephron advances let it deliver supplies to hospitals faster than ever see more
Nephron Pharmaceuticals Corp., headquartered in West Columbia, has announced the implementation of a microbial testing tool that the generic respiratory medication manufacturer says will help it deliver medical supplies to hospitals faster than ever.
Growth Direct, developed by Massachusetts-based lab equipment supplier Rapid Micro Biosystems, automates the incubation, colony counting and data entry of microbial environment testing, according to a Nephron news release. The tool also detects microbial growth 50% faster than human eye.
“We work hard, day in and out, to deliver safe, effective and affordable life-saving medications as efficiently as possible,” Nephron CEO Lou Kennedy said in the release. “Automating our microbial monitoring process allows us to produce safer drugs faster and decreases the shortage of opioid-free pain medication currently facing our nation’s hospitals.”
Growth Direct will allow Nephron’s 503(b) outsourcing division, which produces pre-filled sterile syringes and IV bags, to deliver medical supplies more quickly, the release said.
“We're excited that Nephron Pharmaceuticals Corp. has joined the growing list of global pharmaceutical manufacturers who are upgrading and automating their QC Microbial testing methods with the Growth Direct,” Rapid Micro Biosystems CEO Rob Spignesi said. “And we are proud to help Nephron Pharmaceuticals reduce the shortage of important drugs that help make surgery safer and less painful for patients across the country.”
Commerce Office of Innovation introduces Scribble for the innovation community see more
COLUMBIA, S.C. - The S.C. Department of Commerce's Office of Innovation today announced the launch of Scribble - an online tool for the state's innovation community. Providing individuals and businesses a platform to access resources, this new site is designed to highlight South Carolina's exceptional ingenuity and create a common place for users to access a variety of helpful tools.
"South Carolina's burgeoning innovation sector has come a long way, and this new, state-of-the-art platform will ensure that entrepreneurs have all they need to thrive," said Secretary of Commerce Bobby Hitt. "Inspired by our human nature to document or write down that 'ah-ha' moment, we're excited to celebrate our innovators through Scribble."
With access to company video features, podcasts, blogs and events, Scribble allows users to create a profile to save resources and content, further enhancing the innovation community's connectivity. Launched at the 2019 DigSouth Tech Summit in Charleston, S.C., Scribble will help innovators connect with startup programs, venture capital and other resources around the state.
For more information, visit www.scribblesc.com.
SEMDA Medtech to Showcase Over 20 High-Impact New Technologies, National Speakers at May 2-4 ConferenceLeading-edge innovators, top presenters headed for SEMDA's Medtech 2018 in South Carolina see more
Leading-edge innovators present for recognition, reward at annual gathering of Southeastern who’s who in medical technology, devices and diagnostics
Greenville, SC – April 27, 2018 – At least 23 organizations ranging from start-ups to well-established companies have been accepted to present their latest, ground-breaking innovations to entrepreneurs, innovators, angel investors and business leaders from across the life sciences space as the Southeastern Medical Device Association (SEMDA) 2018 Medtech Conference convenes in Greenville, SC May 2-4, 2018.
SEMDA -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has invited 23 finalist companies to present at PitchRounds 2018 – a highly targeted venue for both “Seed” companies as well as later-stage organizations to present innovative ideas to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others.
Companies from seven Southeastern states will present ground-breaking ideas and technologies to hundreds of industry leaders. Host state South Carolina leads the way with 10 companies invited to present, followed by Georgia and Florida with three companies each. North Carolina, Alabama, Virginia and Tennessee are also represented.
Among the South Carolina companies invited to present are Zylo Therapeutics, Accessible Diagnostics, KIYATEC and Moterum from host city Greenville, while Charleston’s Sanguine Technologies and Cryogenix, and Columbia’s Proof Biotechnologies are also invited.
Invitees from Georgia include Intent Solutions and nfant, both of Atlanta, while North Carolina entries include Diamond Othopedic of Charlotte. Memphis, Tennessee’s Sweetbio, Birmingham’s Circulogene and Nashville’s Raiven are also featured invitees.
Twelve Early-stage companies from the Carolinas, Alabama and Florida have been invited to present at PitchRounds, with four finalists to be selected to compete for $10,000 in prize money, while getting to meet investors and partners at sessions and networking receptions. SCBIO, SCRA and global law firm Eversheds Sutherland are co-sponsors of PitchRounds.
Among the featured speakers committed to present at the conference are keynoter Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.
Joe Lee is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Widely respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.
Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.
Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition. She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).
“The Southeastern medtech industry as a whole shows incredible growth and promise, and the diverse entries from across the region reflect that growth,” said Jason Rupp, Executive Director of SEMDA. “PitchRounds gives us the chance to see the future come to life before our eyes with cutting-edge innovation and game-changing advancements in medical technology, devices and diagnostics from some of America’s brightest minds.”
The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is strong but space is still available, noted Mr. Rupp. Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.
“These presenters and companies demonstrate that SEMDA has evolved into a truly regional organization that embraces and represents a diverse collective of medtech startups, universities, corporate organizations, investment resources, suppliers and capabilities from across the southeastern United States,” Mr. Rupp added.
The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.
Invited and scheduled to present at PitchRounds 2018
LATER STAGE (RAISING SERIES A OR LATER)
Kayla Rodriguez Graff
Sanguine Technologies Inc.
Accessible Diagnostics, LLC
Luke Marshall, Ph.D.
Aravis BioTech LLC
DiaTech Diabetes Technology
Proof Biotechnologies, Inc
PivotSC LLC/ XtremedX